Voyager Therapeutics (NASDAQ:VYGR) reported quarterly losses of $(0.16) per share which beat the analyst consensus estimate of $(0.46) by 65.22 percent. The company reported quarterly sales of $24.60 million which beat the analyst consensus estimate of $11.89 million by 106.87 percent. This is a 433.16 percent increase over sales of $4.61 million the same period last year.